An interventional study of Tangible Boost and Placebo saline in Contact Lens Solution, sponsored by Tangible Science. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.
Sponsored by Tangible Science · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating improves lens wettability, a common cause of patient discomfort. Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.
Tangible Science is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
Device: Tangible Boost
Participants will treat their lenses with a placebo "Tangible Boost" kit containing saline after 30 days and again after 60 days.
Other: Placebo saline
Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
Participants will treat their lenses with a placebo "Tangible Boost" kit, which contains saline in place of the Tangible Boost solution.
Number of Patients With Adverse Event Reports or Discontinuations
A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.
Time frame: Duration of study, 90 +/- 7 days after lens dispense visit.
Corneal Staining
Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.
Time frame: 1 day after treatment (day 31), final assessment (day 90)
Visual Acuity
Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.
Time frame: 1 day after treatment (day 31), final assessment (day 90)
Non-invasive Tear Film Break-up Time
Tear break-up time was measured with the OCULUS Keratograph.
Time frame: 1 day after treatment (day 31), final assessment (day 90)
Number of Participants With Acceptable Lens Fit
Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).
Time frame: final assessment (day 90)
CLDEQ Score
The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.
Time frame: 1 day after treatment (day 31), final assessment (day 90)
Visual Analog Scale (VAS)
The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.
Time frame: 1 day after treatment (day 31), final assessment (day 90)
| Milestone | Tangible Boost | Control | Unassigned |
|---|---|---|---|
| Started | 21 | 10 | 4 |
| Completed | 21 | 10 | 0 |
| Not completed | 0 | 0 | 4 |
A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.
| Participants | Tangible Boost | Control | Unassigned |
|---|---|---|---|
| Number of Patients With Adverse Event Reports or Discontinuations | 4 | 2 | 4 |
Corneal staining with lissamine green was used to identify damage to the corneal cells, which may have been caused by the contact lenses or treatments in the study. 5 regions in each eye were scored on a scale of 0-4, resulting in a total possible range of 0-20. Left and right eye scores were averaged for each subject. A lower score indicates less corneal damage.
| score on a scale | Tangible Boost | Control |
|---|---|---|
| 1 day after treatment | 2.25 (.5 to 5.125) | 2.00 (.75 to 4.50) |
| Final assessment | 1.5 (0 to 3.25) | 1.75 (0.75 to 4.375) |
Visual acuity was calculated on a logMAR scale using high luminance, high contrast acuity charts. On the logMAR scale, a score of 0 indicates no vision loss, with higher scores indicating more vision loss.
| logMAR visual acuity | Tangible Boost | Control |
|---|---|---|
| 1 day after treatment | 0.12 (-.025 to 0.165) | 0.095 (-0.07 to 0.225) |
| final assessment | 0.140 (0.020 to 0.225) | 0.060 (-0.0225 to 0.2725) |
Tear break-up time was measured with the OCULUS Keratograph.
| seconds | Tangible Boost | Control |
|---|---|---|
| 1 day after treatment | 16.27 ± 4.32 | 19.84 ± 6.37 |
| final assessment | 15.84 ± 4.64 | 18.30 ± 3.49 |
Count of participants with acceptable lens fit (movement, centration, apical clearance, limbal clearance, and landing zone).
| Participants | Tangible Boost | Control |
|---|---|---|
| Number of Participants With Acceptable Lens Fit | 21 | 10 |
The Contact Lens Dry Eye Questionnaire (CLDEQ) is used to evaluate the dry eye symptomology of contact lens wearers on a scale of 0-39. A lower score is indicative of greater comfort.
| score on a scale | Tangible Boost | Control |
|---|---|---|
| 1 day after treatment | 14.2 ± 8.9 | 7.9 ± 7.7 |
| final assessment | 16.7 ± 8.0 | 11.4 ± 9.5 |
The subjective comfort of lenses was evaluated on a scale of 0-100, with higher scores indicating better comfort.
| score on a scale | Tangible Boost | Control |
|---|---|---|
| 1 day after treatment | 78 ± 23 | 93 ± 9 |
| final assessment | 75 ± 22 | 84 ± 20 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tangible Boost | 0/21 (0%) | 0/21 (0%) | 4/21 (19%) |
| Control | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Unassigned | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Tangible Boost | Control | Unassigned |
|---|---|---|---|
| Corneal HydropsEye disorders | 0/21 | 0/10 | 1/4 |
| Acute inflammatory conjunctivitisEye disorders | 0/21 | 1/10 | 0/4 |
| Mild conjunctival inflammationEye disorders | 0/21 | 1/10 | 0/4 |
| Respiratory InfectionRespiratory, thoracic and mediastinal disorders | 1/21 | 0/10 | 0/4 |
| Asymptomatic keratitisEye disorders | 1/21 | 0/10 | 0/4 |
| Mild, allergic-type reactionEye disorders | 1/21 | 0/10 | 0/4 |
| Preservative toxicity-type corneal sensitivityEye disorders | 1/21 | 0/10 | 0/4 |
| Contact lens associated red eyeEye disorders | 1/21 | 0/10 | 0/4 |
Baseline measures are provided for all participants who were assigned to a study arm. Participants who dropped out of the study prior to assignment are not included.
| Age, Continuous(years) | Tangible Boost | Control | Total |
|---|---|---|---|
| Mean | 47 ± 16 | 46 ± 16 | 47 ± 15 |
| Sex: Female, Male(Participants) | Tangible Boost | Control | Total |
|---|---|---|---|
| Female | 15 | 4 | 19 |
| Male | 6 | 6 | 12 |
| Race and Ethnicity Not Collected(Participants) | Tangible Boost | Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Tangible Boost | Control | Total |
|---|---|---|---|
| United States | 21 | 10 | 31 |
| Corneal Staining(units on a scale) | Tangible Boost | Control | Total |
|---|---|---|---|
| Median | 2.0 (0.25 to 3.75) | 2.0 (0 to 5.63) | 2.0 (0 to 4.5) |
| Visual Acuity (logMAR)(units on a scale) | Tangible Boost | Control | Total |
|---|---|---|---|
| Median | 0.11 (0.01 to 0.20) | 0.11 (-0.02 to 0.23) | 0.11 (0 to 0.20) |
| Non-invasive tear film break-up time(seconds) | Tangible Boost | Control | Total |
|---|---|---|---|
| Mean | 17.40 ± 4.81 | 14.91 ± 6.48 | 16.59 ± 5.60 |
| Lens Fit(Participants) | Tangible Boost | Control | Total |
|---|---|---|---|
| Count of participants | 21 | 10 | 31 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Feb 2019, 23 months.
Results were first posted in Nov 2020, 1 year 9 months after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tangible Science